SCHEDULE 13D/A

Neumora Therapeutics Inc

Common Stock, $0.0001 par value · CUSIP: 640979100

Event date: 2025-10-27

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• ARCH Venture Fund VII, L.P.Reported CIK 0001402439

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Fund VIII Overage, L.P.Reported CIK 0001617237

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Fund X, L.P.Reported CIK 0001757011

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Fund X Overage, L.P.Reported CIK 0001757017

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Fund XII, L.P.Reported CIK 0001906837

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners VII, L.P.Reported CIK 0001544444

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners X, L.P.Reported CIK 0001782583

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners X Overage, L.P.Reported CIK 0001768905

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners XII, L.P.Reported CIK 0001979765

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners VII, LLCReported CIK 0001544443

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners VIII, LLCReported CIK 0001616165

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners X, LLCReported CIK 0001769012

  Shares: 33,847,838 · Class: 20.6%

• ARCH Venture Partners XII, LLCReported CIK 0001979548

  Shares: 33,847,838 · Class: 20.6%

• Robert NelsenReported CIK 0001219042

  Shares: 33,847,838 · Class: 20.6%

• Keith CrandellReported CIK 0001219039

  Shares: 33,847,838 · Class: 20.6%

• Clinton BybeeReported CIK 0001219043

  Shares: 3,708,794 · Class: 2.3%

• Kristina BurowReported CIK 0001569248

  Shares: 33,958,967 · Class: 20.7%

• Steven GillisReported CIK 0001229592

  Shares: 31,526,272 · Class: 19.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.